Navigation Links
Hepatitis in Medical Technology
... of direct-acting antivirals for the treatment of hepatitis C."
The company plans to report the ... focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, ... programs or commercialization activities in hepatitis C, or any potential pipeline candidates, ...
... received a vaccine. Reactivation of hepatitis B virus has been reported in patients who are ... if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as: feel ...
... received a vaccine. Reactivation of hepatitis B virus has been reported in patients who are ... if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as: feel ...
... studies address key questions in the treatment of hepatitis C COPENHAGEN, Denmark, April 27 ... studies address longstanding questions in the hepatitis C research community and provide important ... are constantly looking for ways to improve hepatitis C treatment outcomes by increasing response rates ...
... potency in reducing viral load in patients with hepatitis C - NUTLEY, N.J., BRISBANE, Calif., and ... of patients chronically infected with the hepatitis C virus (HCV)(1). The study combined two oral ... "These are exciting times in our fight against hepatitis C, and the investigation of the innovative oral ...
... in the treatment of patients with chronic hepatitis C. The Phase 3 results were the subject of two ... could become a leading treatment for chronic hepatitis C." The Phase 3 studies, known as ACHIEVE 1 ... of interferon-naive patients with chronic hepatitis C. ACHIEVE 1 was conducted in patients infected ...
... in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate the dose and ... needs of a growing population of patients with hepatitis C," said Rob Mitchell, Global Head of Roche's ... being held in Copenhagen, Denmark. About hepatitis C ...
... (ribavirin) for 14 days of treatment in hepatitis C virus (HCV) treatment-naive patients infected ... rates in patients chronically infected with the hepatitis C virus." Viral Kinetic Performance ... idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology ...
... in which patients chronically infected with the hepatitis C virus (HCV) were treated for three days. The ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...
... study showed boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with ... in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the ... 1 is the most common and hardest to treat form of hepatitis C. In Part I of the study, a 48-week ...
... USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with ... the United States failed prior treatment of their hepatitis C virus (HCV) infection, representing a large and ... therapies to meet the needs of patients with hepatitis C." Data from the clinical study supporting ...
... dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon ... treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008). Albinterferon alfa-2b is being ... become a market-leading treatment for chronic hepatitis C." Stefan Zeuzem, M.D., Professor of ...
... first Phase 3 results for Albuferon in chronic hepatitis C, and the data were positive. We will have ... for First of Two Phase 3 Trials in Chronic hepatitis C Patients; Results of Second Phase 3 Trial ... patients with genotypes 2 and 3 chronic hepatitis C. The data showed that the rate of sustained ...
... The study is evaluating IDX184 in treatment-naive hepatitis C genotype-1 infected patients. "We are ... with the progress that we have made in our hepatitis C discovery program in 2008, having successfully ... drugs from three major classes of direct-acting hepatitis C antivirals in clinical development." The ...
... - Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for ... of Albuferon's first Phase 3 trial in chronic hepatitis C. We will have the results of Albuferon's ... in Phase 3 Trial in Genotypes 2 and 3 Chronic hepatitis C; Phase 3 Results in Genotype 1 Patients ...
... innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 ... on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III ... protease inhibitor for treating chronic hepatitis C. The company also announced that it is ...
... in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in ... of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus ...
... by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present ... Recommendations for Prevention and Control of hepatitis C Virus (HCV) Infection and HCV-Related Chronic ... the retreatment response in patients with chronic hepatitis C virus infection. Liver Int. 2007 ...
... showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with ... in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the ... 1 is the most common and hardest to treat form of hepatitis C," said Paul Kwo, M.D., associate professor ...
... virological response (SVR) rates for hepatitis C patients as compared to regimens with another ... included all patients at our clinic who initiated hepatitis C treatment and met basic eligibility criteria," ... poor prognostic factors.(2)(3)(4)(5)(6) About hepatitis C ...
... agonist oral prodrug, also in development for hepatitis C. These data strongly support the potential for ... other agents approved or under investigation for hepatitis C. -- In a poster titled "Antiviral Efficacy of ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...
... on precautionary measures. Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) ... During the clinical development program (n=3063), hepatitis has been reported in 0.5 percent of patients ... liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function ...
... and the investment community." About hepatitis C hepatitis C is a blood-borne infectious disease of the ... 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost ...
... of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the healthy volunteer study, ... (bid). ANA598 is the company's investigational hepatitis C non-nucleoside polymerase inhibitor. Phase I ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...
... patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of ... achieved undetectable HCV RNA levels. About hepatitis C hepatitis C is a blood-borne infectious disease of the ...
... II study of boceprevir, its investigational oral hepatitis C protease inhibitor. The analysis showed a high ... study of 595 treatment-nave patients with chronic hepatitis C virus (HCV) genotype 1. In a 48-week ... search term boceprevir. About hepatitis C ...
... to increase globally, due to the prevalence of hepatitis B and C infections," said Jordi Bruix, ... the United States. (1,2) In addition, chronic hepatitis B (HBV) and C (HCV) viral infections are the ... of Medicine, Asian Liver Center, "FAQ About hepatitis B," February 2008. ...
... Clevudine+Viread(R) in 150 patients with chronic hepatitis B PRINCETON, N.J., July 8 ... National Agency for Research on AIDS and Viral hepatitis (ANRS), with the support of Pharmasset, Inc. ... their combination, for the treatment of chronic hepatitis B virus (HBV) infection in non-cirrhotic ....
... received a vaccine. Reactivation of hepatitis B virus has been reported in patients who are ... if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as: feel ...
... received a vaccine. Reactivation of hepatitis B virus has been reported in patients who are ... if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as: feel ...
... studies address key questions in the treatment of hepatitis C COPENHAGEN, Denmark, April 27 ... studies address longstanding questions in the hepatitis C research community and provide important ... are constantly looking for ways to improve hepatitis C treatment outcomes by increasing response rates ...
... potency in reducing viral load in patients with hepatitis C - NUTLEY, N.J., BRISBANE, Calif., and ... of patients chronically infected with the hepatitis C virus (HCV)(1). The study combined two oral ... "These are exciting times in our fight against hepatitis C, and the investigation of the innovative oral ...
... in the treatment of patients with chronic hepatitis C. The Phase 3 results were the subject of two ... could become a leading treatment for chronic hepatitis C." The Phase 3 studies, known as ACHIEVE 1 ... of interferon-naive patients with chronic hepatitis C. ACHIEVE 1 was conducted in patients infected ...
... in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate the dose and ... needs of a growing population of patients with hepatitis C," said Rob Mitchell, Global Head of Roche's ... being held in Copenhagen, Denmark. About hepatitis C ...
... (ribavirin) for 14 days of treatment in hepatitis C virus (HCV) treatment-naive patients infected ... rates in patients chronically infected with the hepatitis C virus." Viral Kinetic Performance ... idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology ...
... in which patients chronically infected with the hepatitis C virus (HCV) were treated for three days. The ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...
... study showed boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with ... in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the ... 1 is the most common and hardest to treat form of hepatitis C. In Part I of the study, a 48-week ...
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
... studies of clevudine for the treatment of chronic hepatitis B (HBV) infection. Pharmasset recently ... receiving clevudine as prescribed therapy for hepatitis B in South Korea. Though only a small number of ... adefovir for 96 weeks in patients with chronic hepatitis due to infection with e-antigen ...Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
... nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an ... of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus ...... USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with ... the United States failed prior treatment of their hepatitis C virus (HCV) infection, representing a large and ... therapies to meet the needs of patients with hepatitis C." Data from the clinical study supporting ...
... dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon ... treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008). Albinterferon alfa-2b is being ... become a market-leading treatment for chronic hepatitis C." Stefan Zeuzem, M.D., Professor of ...
... first Phase 3 results for Albuferon in chronic hepatitis C, and the data were positive. We will have ... for First of Two Phase 3 Trials in Chronic hepatitis C Patients; Results of Second Phase 3 Trial ... patients with genotypes 2 and 3 chronic hepatitis C. The data showed that the rate of sustained ...
Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
... announced today the advancement of their hepatitis C (HCV) collaboration with a first-in-human ... trial in healthy volunteers. About the hepatitis C Virus hepatitis C is a liver disease affecting more than 170 ...... The study is evaluating IDX184 in treatment-naive hepatitis C genotype-1 infected patients. "We are ... with the progress that we have made in our hepatitis C discovery program in 2008, having successfully ... drugs from three major classes of direct-acting hepatitis C antivirals in clinical development." The ...
... - Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for ... of Albuferon's first Phase 3 trial in chronic hepatitis C. We will have the results of Albuferon's ... in Phase 3 Trial in Genotypes 2 and 3 Chronic hepatitis C; Phase 3 Results in Genotype 1 Patients ...
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
... activity in patients infected with chronic hepatitis C virus (HCV) in this first cohort of the study. ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...Pharmasset Reports Fiscal Year End 2008 Financial Results
... the potential of clevudine to treat hepatitis B (HBV), including its use in lamivudine ... Pharmasset made significant progress with our hepatitis C virus (HCV) programs. R7128, our lead HCV ... of oral therapeutics for the treatment of hepatitis B virus ...Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis
... ), with password: h82a7q. Alcoholic hepatitis is a major cause of morbidity and mortality ... "The relationship between drinking and alcoholic hepatitis is complex. Not all heavy drinkers develop ... only moderately. Though damage from alcoholic hepatitis often can be reversed if patients stop drinking, ...... innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 ... on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III ... protease inhibitor for treating chronic hepatitis C. The company also announced that it is ...
... in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in ... of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus ...
... by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present ... Recommendations for Prevention and Control of hepatitis C Virus (HCV) Infection and HCV-Related Chronic ... the retreatment response in patients with chronic hepatitis C virus infection. Liver Int. 2007 ...
... showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with ... in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the ... 1 is the most common and hardest to treat form of hepatitis C," said Paul Kwo, M.D., associate professor ...
... virological response (SVR) rates for hepatitis C patients as compared to regimens with another ... included all patients at our clinic who initiated hepatitis C treatment and met basic eligibility criteria," ... poor prognostic factors.(2)(3)(4)(5)(6) About hepatitis C ...
... agonist oral prodrug, also in development for hepatitis C. These data strongly support the potential for ... other agents approved or under investigation for hepatitis C. -- In a poster titled "Antiviral Efficacy of ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...
... on precautionary measures. Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) ... During the clinical development program (n=3063), hepatitis has been reported in 0.5 percent of patients ... liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function ...
Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
... evaluation, entitled "Laboratory Evaluation of hepatitis B Rapid Test for Use in Screening Walking Blood ... HBSAG test to use for screening blood donors for hepatitis B ("HBSAG") in the theater of war. The ... of the sensitivity of a test and means that hepatitis B infection can now be identified even with ...... and the investment community." About hepatitis C hepatitis C is a blood-borne infectious disease of the ... 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost ...
... of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the healthy volunteer study, ... (bid). ANA598 is the company's investigational hepatitis C non-nucleoside polymerase inhibitor. Phase I ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...
FDA Approves First Hepatitis B Viral Load Test
... HBV Test, the first assay for quantitating hepatitis B Virus DNA approved in the U.S. The test uses ... application of antiviral therapy along with the hepatitis B vaccine has helped reduce prevalence; however, hepatitis B remains a serious and potentially life ...Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program
... term follow up results from chronically infected hepatitis C patients strongly confirm and exceed positive ... long-term antiviral effect of therapeutic hepatitis C vaccination - Data pave the way and strongly ... clinical Phase II study targeting treatment-naive hepatitis C genotype-1 patients. As previously reported in ...Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
... of clevudine for the treatment of chronic hepatitis B virus (HBV) infection, a $1.0 million increase ... Agency for Research on AIDS and Viral hepatitis (ANRS). Anticipated Highlights -- Announcing ... of oral therapeutics for the treatment of hepatitis B virus ...... patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of ... achieved undetectable HCV RNA levels. About hepatitis C hepatitis C is a blood-borne infectious disease of the ...
... II study of boceprevir, its investigational oral hepatitis C protease inhibitor. The analysis showed a high ... study of 595 treatment-nave patients with chronic hepatitis C virus (HCV) genotype 1. In a 48-week ... search term boceprevir. About hepatitis C ...
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
... inhibitor for the treatment of chronic hepatitis C. Today, Idenix also announced that is has ... are pleased with the progress we have made in our hepatitis C discovery program in the past few months," said ... of direct-acting antivirals for the treatment of hepatitis C." IDX184 Nucleotide Prodrug Polymerase ...... to increase globally, due to the prevalence of hepatitis B and C infections," said Jordi Bruix, ... the United States. (1,2) In addition, chronic hepatitis B (HBV) and C (HCV) viral infections are the ... of Medicine, Asian Liver Center, "FAQ About hepatitis B," February 2008. ...
... Clevudine+Viread(R) in 150 patients with chronic hepatitis B PRINCETON, N.J., July 8 ... National Agency for Research on AIDS and Viral hepatitis (ANRS), with the support of Pharmasset, Inc. ... their combination, for the treatment of chronic hepatitis B virus (HBV) infection in non-cirrhotic ....
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
... (TLR7) mechanism for the treatment of chronic hepatitis C. Based on preclinical pharmacology testing and ... efforts in HCV. As an approach to treat hepatitis C, the TLR7 mechanism is independent from, and ... for 2008, Dr. Worland added, "Because the ANA773 hepatitis C program is highly leveraged off our oncology ...Other ContentsOther Tags
(Date:5/23/2013)... which estrogen suppresses lipid synthesis in the liver, UC ... treating certain liver diseases. , With this finding, ... long-held views in the field. Study results appear in ... Signaling . , "The dogma in the steroid receptor ... located in the nucleus respond to steroid hormones by ...
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3(Date:5/23/2013)... Special Learning, Inc., a leading global ... the autism, Down syndrome and special needs community, ... global autism treatment center and Special Education (SPED) ... world-class program is the first of its kind, ... treat and deliver exceptional education outcomes to individuals ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Netsmart ... Top 100 listing of healthcare information technology (HIT) providers for ... June 2013 issue of Healthcare Informatics magazine. Netsmart’s ... list. , “Our strong continued growth is largely due to ... this tumultuous period of healthcare where resources are scarce, the ...
(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Six ... a million dollars by Lyme Research Alliance, the nation's ... major academic institutions. The studies focus on the epidemiology of, ... diseases. , “LRA is proud to support the ... and the brightest men and women in the field ...
(Date:5/23/2013)... 23, 2013) Aortic arch pulse wave velocity, a ... of disease of the vessels that supply blood to ... the June issue the journal Radiology . ... functional information about vessel compliance that may help determine ... said Kevin S. King, M.D., assistant professor of radiology ...
(Date:5/23/2013)... advanced heart-failure patients over the past two decades ... and use of new therapies, overall mortality has ... rapid onset of severe abnormal heart rhythms, has ... that even today, with these significant improvements, one-third ... after being diagnosed with advanced disease. Heart failure ...
Breaking Medicine News(10 mins):Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 3Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:MRI-based measurement helps predict vascular disease in the brain 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3[0] Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines[0] Netsmart Named to Healthcare Informatics Top 100 List[0] Six Investigators Awarded Lyme Research Alliance Grants[0] MRI-based measurement helps predict vascular disease in the brain[0] Death rates decline for advanced heart failure patients, but outcomes are still not ideal
SurchDigiStimMicroStimStimuplexMinistimSoloStimINOventAisysCentivaVacurectOptilenePremileneCelsiusDingo
Other Tags| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |